{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:46:16Z","timestamp":1783647976266,"version":"3.55.0"},"reference-count":16,"publisher":"Scientific Scholar","content-domain":{"domain":["surgicalneurologyint.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"st1\">\n<jats:title>Background: <\/jats:title>\n<jats:p>In the treatment of giant cell tumor of bone (GCTB), the efficacy and safety of denosumab, a receptor activator nuclear factor \u03ba-B ligand inhibitor, has previously been demonstrated, especially for unresectable tumors. One of the current issues in denosumab treatment for unresectable GCTB is whether it can be discontinued, or whether the dosage or the dosing interval can safely be adjusted, if discontinuation is not possible, to avoid the occurrence of side effects.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st2\">\n<jats:title>Case Description: <\/jats:title>\n<jats:p>A 15-year-old boy with diplopia was referred to our hospital after a space-occupying lesion in the sphenoid bone was found on head CT. Partial removal of the tumor was performed through an endoscopic endonasal approach, and pathological diagnosis was confirmed as GCTB. Thereafter, the patient received 120 mg subcutaneous injections of denosumab every 28 days for the first 2 years. Since bone formation was induced and sustained along with tumor reduction, the dosing interval was gradually extended, with 4 monthly dosing for the next 1 year, followed by 6 monthly dosing for the succeeding 2 years. With the extension of the dosing interval, the ossified tumor has regrown slightly, but within an acceptable range.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st3\">\n<jats:title>Conclusion: <\/jats:title>\n<jats:p>Discontinuation of denosumab treatment for unresectable GCTB was not thought to be possible for the current case due to the nature of the drug, as reported in the literature. Extending the dosing interval up to 6 monthly, as could be done safely in the current case, can be considered a useful and appropriate measure.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/sni_439_2020","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T08:41:54Z","timestamp":1604652114000},"page":"370","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dosing interval adjustment of denosumab for the treatment of giant cell tumor of the sphenoid bone: A case report"],"prefix":"10.25259","volume":"11","author":[{"given":"Motoki","family":"Tanikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhito","family":"Mase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"key":"10.25259\/SNI_439_2020\/ref-1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13052-017-0353-0","article-title":"Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female-a case report and literature review","volume":"43","author":"Bardakhchyan","year":"2017","journal-title":"Ital J Pediatr"},{"key":"10.25259\/SNI_439_2020\/ref-2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised freedom trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.25259\/SNI_439_2020\/ref-3","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.25259\/SNI_439_2020\/ref-4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2214\/ajr.144.5.955","article-title":"Caldwell lecture. Giant cell tumor of bone: Highlights of 407 cases","volume":"144","author":"Dahlin","year":"1985","journal-title":"AJR Am J Roentgenol"},{"key":"10.25259\/SNI_439_2020\/ref-5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.blo.0000069890.31220.b4","article-title":"Radiation therapy for giant cell tumors of bone","volume":"411","author":"Feigenberg","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"10.25259\/SNI_439_2020\/ref-6","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1055\/s-0038-1645885","article-title":"Giant cell tumor of the lateral skull base: Diagnostic and management options","volume":"79","author":"Gamboa","year":"2018","journal-title":"J Neurol Surg Rep"},{"key":"10.25259\/SNI_439_2020\/ref-7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3171\/2016.3.JNS152802","article-title":"Treatment of a skull-base giant cell tumor with endoscopic endonasal resection and denosumab: Case report","volume":"126","author":"Goto","year":"2017","journal-title":"J Neurosurg"},{"key":"10.25259\/SNI_439_2020\/ref-8","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.ejca.2014.06.003","article-title":"Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone","volume":"50","author":"Gouin","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.25259\/SNI_439_2020\/ref-9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.anndiagpath.2007.09.002","article-title":"Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in Western India","volume":"12","author":"Gupta","year":"2008","journal-title":"Ann Diagn Pathol"},{"key":"10.25259\/SNI_439_2020\/ref-10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/03008207.2013.848202","article-title":"Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone","volume":"54","author":"Lau","year":"2013","journal-title":"Connect Tissue Res"},{"key":"10.25259\/SNI_439_2020\/ref-11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.coc.0000195089.11620.b7","article-title":"Giant cell tumor of bone","volume":"29","author":"Mendenhall","year":"2006","journal-title":"Am J Clin Oncol"},{"key":"10.25259\/SNI_439_2020\/ref-12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3892\/mco.2017.1137","article-title":"Successful treatment with denosumab in a patient with sacral giant cell tumor of bone refractory to combination therapy with arterial embolization and zoledronic acid: A case report","volume":"6","author":"Nishimura","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.25259\/SNI_439_2020\/ref-13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: An open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.25259\/SNI_439_2020\/ref-14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/CCO.0b013e32832c951d","article-title":"Giant cell tumour of bone","volume":"21","author":"Thomas","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"10.25259\/SNI_439_2020\/ref-15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2017.02.021","article-title":"Giant cell tumour of bone in the denosumab era","volume":"77","author":"van der Heijden","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.25259\/SNI_439_2020\/ref-16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1634\/theoncologist.2013-0432","article-title":"The clinical approach toward giant cell tumor of bone","volume":"19","author":"van der Heijden","year":"2014","journal-title":"Oncologist"}],"container-title":["Surgical Neurology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/surgicalneurologyint.com\/dosing-interval-adjustment-of-denosumab-for-the-treatment-of-giant-cell-tumor-of-the-sphenoid-bone-a-case-report\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/surgicalneurologyint.com\/surgicalint-articles\/dosing-interval-adjustment-of-denosumab-for-the-treatment-of-giant-cell-tumor-of-the-sphenoid-bone-a-case-report\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T08:41:57Z","timestamp":1604652117000},"score":1,"resource":{"primary":{"URL":"http:\/\/surgicalneurologyint.com\/surgicalint-articles\/dosing-interval-adjustment-of-denosumab-for-the-treatment-of-giant-cell-tumor-of-the-sphenoid-bone-a-case-report\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":16,"alternative-id":["10.25259\/SNI_439_2020"],"URL":"https:\/\/doi.org\/10.25259\/sni_439_2020","relation":{},"ISSN":["2152-7806"],"issn-type":[{"value":"2152-7806","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"article-number":"370"}}